TRAPPC11
protein-codingtrafficking protein particle complex subunit 11, the group of Trafficking protein particle complex subunits
Gene summary
The protein encoded by this gene is a subunit of the TRAPP (transport protein particle) tethering complex, which functions in intracellular vesicle trafficking. This subunit is involved in early stage endoplasmic reticulum-to-Golgi vesicle transport. Alternative splicing of this gene results in multiple transcript variants. [provided by RefSeq, Jan 2013]
- C4orf41
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~54.3 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0014144
Submitter: PanelApp Australia
Inheritance Pattern: AR
Disease ID:MONDO:0014144
Submitter: Myriad Women's Health
Inheritance Pattern: AR
Disease ID:MONDO:0014144
Submitter: G2P
Inheritance Pattern: AR
Disease ID:MONDO:0014144
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AR
Disease ID:MONDO:0014144
Submitter: Laboratory for Molecular Medicine
This gene-disease relationship has undergone rapid assessment. Classifications are based on preliminary review of gene-disease validity during analysis of genomic sequencing results.
Inheritance Pattern: AR
Disease ID:MONDO:0015152
Submitter: ClinGen
*TRAPPC11* was first reported in relation to autosomal recessive limb-girdle muscular dystrophy (LGMDR18 included) in 2013 (Bögershausen et al., PMID: 23830518). Autosomal recessive limb-girdle muscular dystrophy is typically characterized by childhood-onset of proximal muscle weakness resulting in gait abnormalities and scapular winging. Many patients have elevated serum creatine kinase. A subset of patients displayed hyperkinetic movement disorder with chorea, ataxia, or dystonia and global developmental delay. Additional phenotypes such as alacrima, achalasia, cataracts, or hepatic steatosis have been observed in the literature. *TRAPC11* has been noted to be associated with autosomal recessive limb-girdle muscular dystrophy, although many authors have noted a phenotypic expansion in the literature, where the term *TRAPPC11*-related myopathy has been coined. ORPHANET lists intellectual disability-hyperkinetic movement-truncal ataxia syndrome (ORPHA:369847) and Triple A syndrome (ORPHA:869) as additional gene-disease assertions. For the purposes of this curation, cases have been scored under the autosomal recessive limb-girdle muscular dystrophy (LGMDR18 included) disease entity, which falls under the umbrella term of *TRAPPC11*-related myopathies in MONDO. Evidence supporting this gene-disease relationship includes case-level data, segregation data, and experimental data. Summary of Case Level Data: 12 POINTS. Variants in this gene have been reported in at least 14 probands in 9 publications (PMIDs: 23830518, 26322222, 27707803, 28827486, 31575891, 30105108, 29855340, 27862579, 34648194). Variants in this gene segregated with disease in 7 additional family members in 2 families (PMID:23830518). Not all probands were scored due to the absence of in trans confirmation of compound heterozygous variants, however, the maximum score for genetic evidence of 12 points has been reached. The majority of pathogenic variants in *TRAPPC11* reported in ClinVar are nonsense or frameshift variants where loss of function is the mechanism of disease. Summary of Experimental Data: 2.5 POINTS. This gene-disease association is also supported by animal model and functional alteration in human cell line (PMID: 26912795, 21525244). Loss-of-function mutations in the zebrafish ortholog of C11 have been found in the foie gras mutant, characterized by steatohepatitis and eye development defects (PMID:26912795). Mutant *TRAPPC11* zebrafish exhibits a phenotype similar to that observed in humans with respect to Golgi complex formation and endoplasmic reticulum organization supporting the role of *TRAPPC11* in the characteristic muscle phenotypes. Research conducted using HeLa cell lines revealed the role of *TRAPPC11* subunit it protein glycosylation. In HeLa cells siRNA knockdown of C11 leads to impaired binding of other TRAPP components, functional impairment of the complex, retention of secretory proteins in the ERGIC, and fragmentation of the Golgi apparatus (PMID:21525244). In summary, there is definitive evidence to support this gene-disease relationship. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the ClinGen Limb-Girdle Muscular Dystrophy GCEP on the meeting date of December 14th, 2021 (SOP Version 8).
Inheritance Pattern: AR
Disease ID:MONDO:0009279
Submitter: Orphanet
Inheritance Pattern: AR
Disease ID:MONDO:0018243
Submitter: Orphanet
Inheritance Pattern: AR
Disease ID:MONDO:0014144
Submitter: Orphanet
Clinical Genomic Database (CGD)
Manifestation: Musculoskeletal; Neurologic
Intervention: General
Rationale: Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to TRAPPC11 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_021942.6. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 12 | 238 | 1 | 251 | ||
| missense | 5 | 424 | 19 | 2 | 450 | |
| nonsense | 12 | 11 | 3 | 26 | ||
| start loss | 1 | 1 | ||||
| frameshift | 18 | 14 | 32 | |||
| splice donor/acceptor (+/-2bp) | 1 | 15 | 3 | 19 | ||
| Total | 31 | 45 | 443 | 257 | 3 | 779 |
Highest pathogenic variant AF is 0.00006485206
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_068761.4 | 29 | MANE Select | |
| Ensembl | ENSP00000335371.6 | 29 | MANE Select | |
| RefSeq | NP_951008.1 | 30 | Standard | |
| Ensembl | ENSP00000349738.4 | 30 | Standard |
Model Organisms & Knockout Phenotypes
Observed phenotypic effects in mouse and zebrafish models
| Gene / Model | Organism | Observed Phenotype |
|---|---|---|
| trappc11 | Danio rerio | Structure: hepatocyte Quality: increased size abnormal |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Vesicle-mediated transport
- Membrane Trafficking
- Rab regulation of trafficking
- RAB GEFs exchange GTP for GDP on RABs
Biological Process
- endoplasmic reticulum to Golgi vesicle-mediated transport
- Golgi organization
- protein complex oligomerization
- regulation of protein complex stability
Molecular Function
- protein binding
- Rab guanyl-nucleotide exchange factor activity
Cellular Component
- Golgi apparatus
- cytosol
- TRAPP complex
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000334690
- Coding exons
- 29
- Length
- 54326
- Individuals with no LoFs
- 125670
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 78
- Defined
- 125748
- p
- 0.000310
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 0.932 | 534 | 598 | 0.893 | 0.0000300 | 7426 |
| Missense (PolyPhen) | 68 | 92.014 | 0.73902 | 1085 | ||
| Synonymous | 0.533 | 209 | 219 | 0.954 | 0.0000119 | 2132 |
| Loss of Function | 4.46 | 28 | 67.5 | 0.415 | 0.00000349 | 814 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.00025 | 0.00025 | rare |
| Latino/Admixed American | 0.00036 | 0.00035 | rare |
| Ashkenazi Jewish | 0.000099 | 0.000099 | rare |
| East Asian | 0.00034 | 0.00033 | rare |
| Finnish | 0.000092 | 0.000092 | rare |
| European (Non-Finnish) | 0.00039 | 0.00039 | rare |
| South Asian | 0.00031 | 0.00029 | rare |
| Other | 0 | 0.0 | absent |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Involved in endoplasmic reticulum to Golgi apparatus trafficking at a very early stage. {ECO:0000269|PubMed:21525244, ECO:0000269|PubMed:27862579}.;
- Disease
- DISEASE: Limb-girdle muscular dystrophy 2S (LGMD2S) [MIM:615356]: A form of limb-girdle muscular dystrophy characterized by proximal muscle weakness with childhood onset, resulting in gait abnormalities and scapular winging. Serum creatine kinase is increased. A subset of patients may show a hyperkinetic movement disorder with chorea, ataxia, or dystonia and global developmental delay. {ECO:0000269|PubMed:23830518}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.106
Intolerance Scores
- RVIS EVS
- -0.97
- RVIS percentile EVS
- 8.99
Essentials
- Essential (CRISPR)
- E
- Essential (CRISPR2)
- E
- Essential (gene trap)
- E
- Indispensability pred.
- N
- Indispensability score
- 0.114
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |